MAP2K1 and cancer: To further examine possible RTK-SHP2 dependency correlations, we took advantage of a high-throughput pharmacological profiling of anti-cancer agents that included RTK inhibitors such as erlotinib (EGFR) and BGJ398 (FGFRs) [20] as well as SHP099 (allosteric SHP2 inhibitor) [10], and trametinib (MEK1/2 inhibitor) across 262 cancer cell lines.